Moracin M
(Synonyms: 桑辛素M) 目录号 : GC39539
Moracin M是一种磷酸二酯酶4（PDE4）抑制剂（PDE4D2：IC50 = 2.9μM；PDE4B2：IC50 = 4.5μM；PDE5A1：IC50 > 40μM；PDE9A2：IC50 > 100μM）。
Cas No.:56317-21-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Moracin M is a phosphodiesterase 4 (PDE4) inhibitor (PDE4D2: IC50 = 2.9μM; PDE4B2: IC50 = 4.5μM; PDE5A1: IC50 > 40μM; PDE9A2: IC50 > 100μM) [1]. Moracin M inhibits inflammatory signaling pathways such as NF-κB and MAPK, reducing the production of pro-inflammatory cytokines (such as TNF-α, IL-6, and NO) [2-3]. Moracin M is often used in inflammation research [4].
In human umbilical vein endothelial cells (HUVECs), Moracin M (6.25-25µg/mL;24h) enhances HUVEC tube formation in a dose-dependent manner [5]. In C2C12 cells, Moracin M (25 μM; 48 h) treatment significantly increased myoblast proliferation [6].
In acute lung injury mice model, Moracin M (20mg/kg, 60mg/kg; ig; single administration) inhibits airway inflammation [7]. In LPS-induced mouse airway inflammation model, Moracin M (30mg/kg; po; single administration) effectively reduces airway inflammation in vivo [8].
References:
[1]. Chen S K, Zhao P, Shao Y X, et al. Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor[J]. Bioorganic & medicinal chemistry letters, 2012, 22(9): 3261-3264.
[2]. Yao X, Wu D, Dong N, et al. Moracin C, a phenolic compound isolated from Artocarpus heterophyllus, suppresses lipopolysaccharide-activated inflammatory responses in murine raw264. 7 macrophages[J]. International Journal of Molecular Sciences, 2016, 17(8): 1199.
[3]. Chen L, Wu D, Wang S, et al. Moracin M derivative targeting PDE4 for the treatment of psoriasis[J]. Acta Materia Medica, 2025, 4(2): 293-301.
[4]. Guo F, Zou Y, Zheng Y. Moracin M inhibits lipopolysaccharide-induced inflammatory responses in nucleus pulposus cells via regulating PI3K/Akt/mTOR phosphorylation[J]. International immunopharmacology, 2018, 58: 80-86.
[5]. Chang B Y, Hwang Y, Kim I, et al. The Role of Moracin M in Promoting Hair Growth: Insights into Mechanisms of WNT/β-Catenin Pathway Activation and Angiogenesis Enhancement in Human Dermal Papilla Cells[J]. 2024.
[6]. Kwak H J, Kim J, Kim S Y, et al. Moracin E and M isolated from Morus alba Linné induced the skeletal muscle cell proliferation via PI3K-Akt-mTOR signaling pathway[J]. Scientific reports, 2023, 13(1): 20570.
[7]. Lee J H, Ko H J, Woo E R, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo[J]. European journal of pharmacology, 2016, 783: 64-72.
[8]. Lee J, Mandava S, Ahn S H, et al. Potential moracin M prodrugs strongly attenuate airway inflammation in vivo[J]. Biomolecules & Therapeutics, 2020, 28(4): 344.
Moracin M是一种磷酸二酯酶4（PDE4）抑制剂（PDE4D2：IC50 = 2.9μM；PDE4B2：IC50 = 4.5μM；PDE5A1：IC50 > 40μM；PDE9A2：IC50 > 100μM） [1]。Moracin M抑制NF-κB和MAPK等炎症信号通路，从而减少促炎细胞因子（如TNF-α、IL-6和NO）的产生 [2-3]。Moracin M常用于炎症研究 [4]。
在人脐静脉内皮细胞（HUVEC）中，Moracin M（6.25-25µg/mL；24h）以剂量依赖性方式增强HUVEC管腔形成 [5]。在C2C12细胞中，Moracin M（25μM；48h）处理显著促进成肌细胞增殖 [6]。
在急性肺损伤小鼠模型中，Moracin M（20mg/kg，60mg/kg；ig；单次给药）可抑制气道炎症 [7]。在LPS诱发的小鼠气道炎症模型中，Moracin M（30mg/kg；po；单次给药）可有效减轻体内气道炎症 [8]。
| Cell experiment [1]: | |
Cell lines | Human umbilical vein endothelial cells (HUVECs) |
Preparation Method | The cell migration capacity was evaluated using a scratch wound-healing assay. A synthetic wound was generated in an 80–90% confluent monolayer of HUVECs cultured in a 24-well plate, employing a 200µL pipette tip. The impact of co-culturing HUVECs with Moracin M at concentrations of 6.25, 12.5, and 25µg/mL on cell migration was observed using microscopy at the 0 and 24-hour marks. |
Reaction Conditions | 6.25-25µg/mL;24h |
Applications | Moracin M enhances HUVEC tube formation in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | Acute lung injury mice model |
Preparation Method | To establish an animal model of acute lung injury (ALI), a modified ALI model was used. Mice were divided into five groups (n = 13): control, LPS, LPS/Moracin M (20mg/kg and 60mg/kg), and LPS/dexamethasone (30mg/kg). The test compound, containing a reference drug, was dissolved in 0.3% sodium carboxymethylcellulose (CMC) solution and administered orally. The control and LPS groups were also given an equal volume of CMC solution. One hour later, LPS (2mg/kg in PBS) was administered intranasally to the mice (10μL/mouse, five times, for a total of 50μL) to induce bronchitis. Sixteen hours after LPS treatment, the mice (n = 7) were sacrificed, and bronchoalveolar lavage (BAL) fluid was collected via endotracheal cannulation. 700μL of PBS was then infused three times. Approximately 2,000μL of BAL fluid was collected per mouse. The total number of cells in BAL fluid was counted using a hemocytometer, and differential cell counts were performed using a fluorescence-activated cell sorter (FACS). For histological and biochemical analyses, mice (n = 3) were sacrificed, and lung tissue was excised. Histological specimens were fixed and prepared for hematoxylin and eosin (H&E) staining. |
Dosage form | 20mg/kg, 60mg/kg; ig; single administration |
Applications | Moracin M inhibits airway inflammation. |
References: | |
| Cas No. | 56317-21-6 | SDF | |
| 别名 | 桑辛素M | ||
| Canonical SMILES | OC1=CC(C2=CC3=CC=C(O)C=C3O2)=CC(O)=C1 | ||
| 分子式 | C14H10O4 | 分子量 | 242.23 |
| 溶解度 | DMSO: 16.67 mg/mL (68.82 mM) | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.1283 mL | 20.6415 mL | 41.2831 mL |
| 5 mM | 825.7 μL | 4.1283 mL | 8.2566 mL |
| 10 mM | 412.8 μL | 2.0642 mL | 4.1283 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet